NEWS

NEWS 2021.6.23 Exhibiting at Arab Health 2021

Professor Hiroshi Kawamoto’s laboratory, Kyoto University, is now making an exhibition of its r...

NEWS 2021.6.8 Our research activity to develop a new T cell therapy for COVID-19 was introduced in the TV program “Hodo Station”

Professor Hiroshi Kawamoto, a director of Rebirthel and the Vice Director of Institute for Fron...

NEWS 2021.5.15 Professor Hiroshi Kawamoto’s research was featured on Sankei Shimbun (Japanese newspaper)

In the evening edition of Sankei Shimbun on May 15th, 2021, Professor Hiroshi Kawamoto’s resear...

NEWS 2021.3.4 The article introducing Rebirthel was published in the web magazine “Nikkei Biotechnology & Business”

Nikkei Biotechnology & Business is the leading news site of biotechnology in Japan. In its ...

NEWS 2020.12.11 Our R&D activity to develop a new T cell therapy for the novel coronavirus infection was introduced on Japanese TV program.

Professor Hiroshi Kawamoto, an excecutive director of Rebirthel, is recently conducting the col...

NEWS 2020.10.15 Collaborative research project between Rebirthel and Fujita Health University – On-side visit video

This video was taken when our executive director, Hiroshi Kawamoto (Professor, Institute for Fr...

NEWS 2020.10.1 Rebirthel concluded the research license agreement with Otsuka Pharmaceutical.

Rebirthel Co., Ltd. (hereafter Rebirthel) concluded the research license agreement with Otsuka ...

NEWS 2020.4.9 Introduction

The world is presently facing the serious situation of the coronavirus pandemic. We all need to...